Diabetic foot disease

Module 3: A look to the future

Please log in to access the chapters in this module.
CME Credits: 1
Module duration: 1 hour
Launch date: Summer 2020 (version 1)
Updated: Winter 2022 (version 2)
Expiry date: March 2027
Audience: Diabetes and Metabolism Specialists (Advanced), Endocrinologists (Advanced), General Physicians (Subspeciality)

Hello, my name is Andrew Boulton and I’m glad to welcome you to this course on the diabetic foot. I’m a Professor of Medicine at the University of Manchester in England, as well as being a Visiting Professor at the University of Miami. I was a past President of the EASD, which I ran from 2011 to 2015 and currently I’m President of the International Diabetes Federation. Now, the diabetic foot was once regarded as the Cinderella of diabetic complications. Nobody was really interested in it, and I remember speaking at a conference in New Zealand when one GP got up and said: “I like looking at the kidney. I like looking at eyes, but I can’t be enthused by feet.” This cannot be the future. We all have to be enthused by feet, because screening for the diabetic foot is so easy and requires no expensive equipment. But in this introduction, I’m going to go through some of the recent developments in the diabetic foot that are really quite exciting. There is now evidence-based medicine for the treatment, and even the prevention, of the diabetic foot, which I will go through in the future slides of this presentation.

Edmonds M. A renaissance in diabetic foot care: new evidence-based treatments. Lancet Diabetes Endocrinol. 2018 Nov;6(11):837-838.
http://pubmed.ncbi.nlm.nih.gov/30243804/

Game F, Jeffcoate W, Tarnow L, Jacobsen JL, Whitham DJ, Harrison EF, Ellender SJ, Fitzsimmons D, Löndahl M; LeucoPatch II trial team. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial Lancet Diabetes Endocrinol. 2018 Nov;6(11):870-878.
https://pubmed.ncbi.nlm.nih.gov/30243803/

Edmonds M, Lázaro-Martinez JL, Alfayate-Garcîa JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piagessi A. Sucrose octasulfate dressing versus controlled dressing in patients with neuroischaemic diabetic foot ulcers (EXPLORER): an international, multi-centre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6: 186-196.
https://pubmed.ncbi.nlm.nih.gov/29275068/

Learning Outcomes

By the end of this module, you will be able to:

Interpret research studies investigating new medications and approaches to infection, including hyperbaric oxygen therapy to treat diabetic foot disease

Explain how SMART technology and advanced temperature monitoring can be used to identify, monitor, support and assess the effectiveness of timely interventions in people with diabetic foot disease

Develop monitoring, assessment and treatment plans for people with diabetic foot disease


This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.


Contributors

Professor
Andrew Boulton
Author, Assessment Setter
Professor
Rayaz A Malik
Expert Reviewer
Assessment Setter